Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan - Quiz - MDSpire

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

  • February 26, 2025

Share

Original Source(s)

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

  • February 26, 2025

Related Content

Multimodal management of late-stage Bockenheimer disease complicated by severe anemia and coagulopathy: a case report

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia